Clinical Response to a PARP Inhibitor and Chemotherapy in a Child with BARD1-Mutated Refractory Neuroblastoma: A Case Report

Despite advances in the treatment of high-risk neuroblastoma, approximately half of these patients die from the disease. Targeted therapy based on synthetic lethality associated with homologous recombination deficiency (HRD) caused by germline mutations in homologous recombination repair genes has s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cupit-Link, Maggie, Hagiwara, Kohei, Zhang, Jinghui, Federico, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462232/
https://www.ncbi.nlm.nih.gov/pubmed/37645774
http://dx.doi.org/10.21203/rs.3.rs-3250117/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462232/
https://www.ncbi.nlm.nih.gov/pubmed/37645774
http://dx.doi.org/10.21203/rs.3.rs-3250117/v1

Ejemplares similares